BioTuesdays
Feature

Triumvira targeting cancer with customized T cells

By Len Zehr Closely-held Triumvira Immunologics is developing a novel platform to engineer the immune system’s T cells to attack cancer using proprietary T Cell-Antigen Couplers (TACs). “TACs were designed to use the...

July 26, 2016
Feature

In conversation with Dr. Paul Lem

By Len Zehr As CEO and a co-founder of Spartan Bioscience, Dr. Paul Lem has led the closely-held company through FDA and Health Canada approval of the Spartan RX CYP2C19 System, a breakthrough technology that provides...

July 19, 2016
Feature

Braeburn taking path as pill-free pharma company

By Len Zehr Closely-held Braeburn Pharmaceuticals, which in late May received FDA approval to market the first ever six-month implant of buprenorphine for opioid dependence, is developing a portfolio of long-acting...

July 12, 2016
Feature

Merus Labs moving up the value chain

By Len Zehr After an 18-month company transformation under new CEO, Barry Fishman, Merus Labs International (NASDAQ:MSLI; TSX:MSL) is now ready to in-license new pharmaceutical products, in addition to optimizing...

July 5, 2016
Feature

Antibe to have Phase 2 pain data by third quarter

By Len Zehr Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee...

June 21, 2016
Feature

ESSA Pharma takes unique approach to prostate cancer

By Len Zehr A marine sponge, Geodia lindgreni, native to Papua New Guinea may hold the key to a new approach in the treatment of prostrate cancer by ESSA Pharma (NASDAQ:EPIX; TSX:EPI). “Our scientific founders from the...

June 7, 2016
Feature

Lipocine advancing pipeline, PDUFA for oral TRT

By Len Zehr With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing...

May 31, 2016
Feature

In conversation with Paul Gunn

By Len Zehr As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by...

April 26, 2016
Feature

Xagenic readies X1 molecular diagnostic beta trials

Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in...

April 19, 2016
Feature

In conversation with Jerry Ropelato

By Len Zehr As CEO and founder of closely-held WhiteClouds, which operates the largest 3D color printing facility in the world, Jerry Ropelato is passionate about using the technology to create stunning models for the...

April 12, 2016
Feature

In conversation with David Luci

By Len Zehr As president, CEO and a co-founder of Dipexium Pharmaceuticals (NASDAQ:DPRX), David Luci, and executive chairman and co-founder, Robert DeLuccia, have spearheaded development of Locilex, which could be the...

March 8, 2016
Feature

In conversation with Charles Haff

By Len Zehr As a senior research analyst at Craig-Hallum Capital Group, Charles Haff covers medical devices and ancillary healthcare services. Previously, he covered medical devices at Dougherty & Company and was a...

February 16, 2016
Feature

In conversation with Amir Ronen

By Len Zehr As a founding member of closely-held Sensible Medical Innovations, Amir Ronen also has held the title of CEO since the company’s inception in late 2007. Mr. Ronen has over 15 years of experience in senior...

February 2, 2016
Feature

In conversation with Dr. Alan Schwebel

By Len Zehr As president and CEO of BioView (TASE:BIOV), Dr. Alan Schwebel has led the company, a world leader in automated fluorescence in situ hybridization (FISH) cell imaging and analysis, since 2009. Dr. Schwebel...

January 26, 2016